Form 4: Key Insider Group Sells Over $200K in Entrada Therapeutics Stock

A group of directors and 10% owners, including 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., sold 27,000 shares of Entrada Therapeutics, Inc. common stock for approximately $202,554.

Summary

• 5AM Ventures V, L.P., a 10% owner and director, sold 20,065 shares of Entrada Therapeutics, Inc. common stock.
• 5AM Opportunities I, L.P., also a 10% owner and director, sold an additional 6,935 shares of common stock.
• Both sales occurred on July 9, 2025, at a price of $7.502 per share.
• The total value of the shares sold by these entities amounts to approximately $202,554.
• Following these transactions, 5AM Ventures V, L.P. directly holds 3,163,066 shares, and 5AM Opportunities I, L.P. indirectly holds 1,093,313 shares.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a director and 10% owner group. Although the sale was pre-planned under a 10b5-1 plan, reducing the immediate negative implication, it still represents a decrease in insider ownership, which can be perceived as a lack of strong conviction or a move to diversify by a key investor.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than a reaction to immediate negative news.

Negatives

• Significant insider selling by a group of directors and 10% owners, totaling 27,000 shares, could be perceived negatively by the market.
• The sale reduces the direct and indirect holdings of a key institutional investor group in the company.

Risks

• Investor sentiment may be negatively impacted by the sale of shares by a significant insider group, potentially leading to downward pressure on the stock price.

Future Outlook

NA

Industry Context

Insider transactions, particularly sales by significant shareholders and directors, are closely watched in the biotechnology and pharmaceutical sectors as they can signal management's confidence or liquidity needs. While a 10b5-1 plan mitigates the immediate negative signal, the reduction in holdings by a major investor group like 5AM Ventures is still noteworthy.

Comparison to Industry Standards

• NA

Related Party Transactions

• The reported transactions involve sales of common stock by entities and individuals (5AM Ventures V, L.P., 5AM Opportunities I, L.P., 5AM Partners V, LLC, 5AM Opportunities I (GP), LLC, Scott M. Rocklage, and Andrew J. Schwab) who are identified as directors and 10% owners of Entrada Therapeutics, Inc., classifying these as related party transactions.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal of reduced confidence from a major investor group, potentially leading to a decrease in share price.
• Employees and other stakeholders might monitor such transactions for insights into the company's perceived value by its insiders.

Key Dates

Recommendation

Keywords

Entrada Therapeutics, TRDA, SEC Form 4, Insider Trading, Stock Sale, 10% Owner, Director, 5AM Ventures, Rule 10b5-1 Plan, Biotechnology, Pharmaceuticals